Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Perrigo Company PLC    PRGO   IE00BGH1M568

PERRIGO COMPANY PLC

(PRGO)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
03/15/2019 03/18/2019 03/19/2019 03/20/2019 03/21/2019 Date
48.15(c) 48.67(c) 49.24(c) 48.35(c) 48.58(c) Last
2 036 766 1 034 979 895 035 902 172 820 576 Volume
+1.67% +1.08% +1.17% -1.81% +0.48% Change
More quotes
Financials (USD)
Sales 2019 4 744 M
EBIT 2019 856 M
Net income 2019 350 M
Debt 2019 2 245 M
Yield 2019 1,50%
Sales 2020 4 808 M
EBIT 2020 906 M
Net income 2020 430 M
Debt 2020 1 842 M
Yield 2020 1,71%
P/E ratio 2019 18,95
P/E ratio 2020 15,42
EV / Sales2019 1,86x
EV / Sales2020 1,76x
Capitalization 6 601 M
More Financials
Company
Perrigo Company PLC (Perrigo), formerly Perrigo Company Limited, is an over-the-counter (OTC) consumer goods and specialty pharmaceutical company. The Company's segments include Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals (Rx) and Specialty Sciences.... 
Sector
Pharmaceuticals
Calendar
05/07Earnings Release
More about the company
Surperformance© ratings of Perrigo Company PLC
Trading Rating : Investor Rating :
More Ratings
Latest news on PERRIGO COMPANY PLC
03/20PERRIGO CO PLC : Change in Directors or Principal Officers, Financial Statements..
AQ
03/19PERRIGO : Announces Tentative FDA Approval for the Generic Version of Finacea Fo..
AQ
03/13PERRIGO : Initial filing by director officer or owner of more than ten percent.
PU
03/08PERRIGO : Amendment to a previously filed 4
PU
03/03PERRIGO Rosen Law Firm Reminds Perrigo Company plc Investors of Important Mar..
BU
03/01Intellia CEO not involved in Starboard's Bristol-Myers board challenge
RE
02/28PERRIGO COMPANY PLC : Ex-dividend day for
FA
02/27PERRIGO : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
02/27PERRIGO CO PLC : Results of Operations and Financial Condition, Financial Statem..
AQ
02/26Theralase Announces Appointment of New Chief Executive Officers
AQ
More news
Analyst Recommendations on PERRIGO COMPANY PLC
More recommendations
Sector news : Pharmaceuticals - NEC
03:47aBIOGEN : Shares Skid After Company Ends Alzheimer's Trials
DJ
01:55aEISAI : starts phase 3 trials for second Alzheimer's drug after first's failure
RE
01:38aUPS eyes in-home health services with U.S. vaccine project
RE
03/21JOHNSON & JOHNSON : J&J to record $700 million charge related to abandoned drug ..
RE
03/21JOHNSON & JOHNSON : J&J to Impair Value of Investigational Antiviral Treatment A..
DJ
More sector news : Pharmaceuticals - NEC
Chart PERRIGO COMPANY PLC
Duration : Period :
Perrigo Company PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PERRIGO COMPANY PLC
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 14
Average target price 61,4 $
Spread / Average Target 26%
EPS Revisions
Managers
NameTitle
Murray S. Kessler President, Chief Executive Officer & Director
Rolf Allan Classon Chairman
Ronald Janish Executive VP-Global Operations and Supply Chain
Ron L. Winowiecki Chief Financial Officer
Thomas Farrington Chief Information Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
PERRIGO COMPANY PLC25.37%6 601
JOHNSON & JOHNSON7.01%365 572
NOVARTIS10.52%237 139
PFIZER-2.98%234 120
ROCHE HOLDING LTD.11.28%234 082
MERCK AND COMPANY8.56%211 867